The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Losing fat specifically
Was it fat that came off, or everything?
Weight is not fat. This is the subset of trials that actually measured what the lost weight was made of, which is a much smaller set than the weight-loss trials.
2,019 people · 19 human studies · 14 compounds
- 1,370 people3 studies1 found nothing
found nothing806 patients pooled across both Phase 3 trials. Visceral fat fell 24 square centimetres at week 26 against a 2 square centimetre rise on placebo, a treatment effect of minus 15.4 percent, with no change in subcutaneous fat. The largest dataset on either component of this blend, and it is tesamorelin monotherapy.
Journal of Clinical Endocrinology and Metabolism, 2010 · 806 people
412 patients with HIV and abdominal fat accumulation. Twenty-six weeks of tesamorelin at 2 mg daily reduced visceral adipose tissue by 15.2 percent against a 5.0 percent increase on placebo, with lower triglycerides. This is tesamorelin alone at 2 mg. No ipamorelin was given, and 2 mg daily is the dose the approval...
New England Journal of Medicine, 2007 · 412 people
152 adults aged 55 to 87, of whom 66 had mild cognitive impairment. Twenty weeks of tesamorelin at 1 mg daily had a favourable effect on cognition, P equal to 0.03, concentrated in executive function, and raised IGF-1 by 117 percent within the physiological range. Note the dose: 1 mg, which is half the dose that...
Archives of Neurology, 2012 · 152 people
- 412 people1 study
412 patients with HIV and abdominal fat accumulation: 26 weeks of tesamorelin 2 mg daily reduced visceral adipose tissue 15.2% versus a 5.0% increase on placebo, with lower triglycerides.
New England Journal of Medicine, 2007 · 412 people
- 84 people2 studies1 found nothing
60 hypopituitary adults on GH for a mean of 10 years were crossed over to four months of placebo. IGF-1 fell from 168 to 98 micrograms per litre, two quality-of-life domains deteriorated, waist circumference and visceral fat rose, and lipids and C-reactive protein worsened, while insulin sensitivity improved.
Journal of Clinical Endocrinology and Metabolism, 2012 · 60 people
found nothingSix months of rhGH in 24 GH-deficient adults raised lean mass by 5.5 kg and cut fat mass by 5.7 kg versus placebo, with no change in body weight.
New England Journal of Medicine, 1989 · 24 people
- 53 people2 studies1 found nothing
30 men with BMI at or above 26, randomised double-blind to 250 mg of a 10 percent forskolin extract twice daily or placebo for 12 weeks. Body fat percentage and fat mass on DXA fell significantly against placebo, bone mass changed significantly, serum free testosterone rose significantly, and lean body mass showed a...
Obesity Research, 2005 · 30 people
found nothing23 women randomised double-blind to 250 mg of a 10 percent Coleus forskohlii extract twice daily (n equals 7) or placebo (n equals 12) for 12 weeks. No significant differences in fat mass, fat-free mass or body fat percentage. Non-significant trends toward mitigating gains in body mass (p equals 0.10) and scanned mass...
Journal of the International Society of Sports Nutrition, 2005 · 23 people
- 50 people1 study
The entire published obesity efficacy record: 50 participants across five dose cohorts and placebo, mean baseline weight 92.9 kg. Mean weight reduction was 7.16 percent against 0.86 percent on placebo, and 82.5 percent of treated participants lost at least 5 percent against none on placebo. Fat mass fell 4.47 kg and...
Diabetes, Obesity and Metabolism, 2026 · 50 people
- 20 people1 study1 found nothing
found nothing20 obese adults, mean age 48 and BMI 37, randomised to 1,750 mg a day of TUDCA or placebo for 4 weeks, with two-stage hyperinsulinaemic-euglycaemic clamps, tracer infusions and muscle and adipose biopsies. Hepatic and muscle insulin sensitivity rose approximately 30 percent (p < 0.05) with no change on placebo, and...
Diabetes, 2010 · 20 people
- 16 people1 study1 found nothing
found nothing16 healthy men, mean age 29, randomised to eight weeks of resistance training alone (n equals 7) or with ursolic acid (n equals 9), one capsule three times daily. Body fat percentage fell significantly in the supplemented group (p less than 0.001) while body weight, body mass index, lean body mass, glucose and insulin...
Korean Journal of Physiology and Pharmacology, 2014 · 16 people
- 11 people1 study1 found nothing
found nothingThe first randomised controlled trial. 11 healthy men aged 18 to 40, two 2-week cycles of oral clenbuterol at 80 micrograms a day versus placebo with a 3-week washout. Lean mass +0.91 kg (95% CI 0.02 to 1.81, p < 0.05), no effect on fat mass, maximal oxygen uptake -7% (p < 0.001), exercise capacity -4% (p < 0.001), no...
The Journal of Physiology, 2025 · 11 people
- 3 people1 study
Three children with congenital leptin deficiency treated with daily subcutaneous recombinant human leptin for up to 4 years: sustained reductions in appetite, fat mass, hyperinsulinaemia and hyperlipidaemia, rapid rise in thyroid hormones, appropriately timed puberty, and reversal of reduced CD4 T cell numbers and...
Journal of Clinical Investigation, 2002 · 3 people
- no headcount stated2 studies2 found nothing
found nothingThe direct contradiction of the trial above. Twenty-four obese but otherwise healthy men, parallel-group, four weeks of high-dose resveratrol. Insulin sensitivity by hyperinsulinaemic euglycaemic clamp, the primary outcome, deteriorated insignificantly in both arms. No effect on blood pressure, resting energy...
Diabetes, 2013 · no headcount in the line
found nothingTwenty overweight or obese men with NAFLD, 3,000 mg daily for eight weeks. No improvement in insulin resistance, steatosis, abdominal fat distribution, plasma lipids or antioxidant activity, and no change in NQO1, PTP1B, IL6 or HO1 transcription. ALT and AST rose significantly versus placebo through week 6, which the...
Clinical Gastroenterology and Hepatology, 2014 · no headcount in the line
- no headcount stated1 study
Triple regimen preserved 80.9% of lean mass with 27.3% more fat loss.
Regeneron press release, 2025 · no headcount in the line
- no headcount stated1 study
Receptor-level blockade rather than myostatin-only blockade, so it neutralises activin A too. At 48 weeks fat mass fell 20.5% (7.5 kg) against 0.5% on placebo, lean mass rose 3.6% (1.7 kg), waist fell 9.0 cm and HbA1c fell 0.76 points, all p < 0.006.
JAMA Network Open, 2021 · no headcount in the line
- no headcount stated1 study
First-in-human in Chinese men with overweight or obesity. Single ascending dose 12 to 120 mg, n = 36, randomised 3:1 active to placebo, plus multiple ascending dose n = 12 escalating 15 to 60 mg. Well tolerated with predominantly mild to moderate gastrointestinal adverse events. Dose-proportional exposure from 12 to...
Diabetes, Obesity and Metabolism, 2026 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingRandomised 2:1, 30 overweight or obese adults aged 45 and over, MIB-626 two 500 mg tablets twice daily for 28 days. Body weight fell 1.9 kg (95 percent CI -3.3 to -0.5, P=.008), diastolic blood pressure fell 7.01 mmHg (-13.44 to -0.59, P=.034), total cholesterol fell 26.89 mg/dL (P=.004) and LDL fell 18.73 mg/dL...
Journal of Clinical Endocrinology and Metabolism, 2023 · no headcount in the line
- no headcount stated0 studies
The C-terminal 177-191 domain of hGH mimicked GH's lipolytic actions on adipose tissue and reduced weight gain in obese rats without insulin resistance.
Journal of Molecular Endocrinology, 2000 · no headcount in the line
30 days of oral hGH fragment (AOD-9401) lowered weight gain in ob/ob mice without changing food intake and increased lipolysis in obese rodent and human adipose tissue ex vivo.
American Journal of Physiology: Endocrinology and Metabolism, 2000 · no headcount in the line
- no headcount stated0 studies
Weight loss confined to adipose tissue.
Obesity, 2010 · no headcount in the line
- no headcount stated0 studies
Peripheral ghrelin increased food intake and body fat in rodents, establishing its role in energy balance.
Nature, 2000 · no headcount in the line
- no headcount stated0 studies
Small-molecule NNMT inhibitors (the 5-amino-1MQ series) reduced body weight and fat mass in diet-induced obese mice.
Biochemical Pharmacology, 2018 · no headcount in the line
- no headcount stated0 studies
Mouse, and the most important comparison for this page. A single exchange of half the plasma volume for saline containing 5 percent albumin, with no young plasma added at all, met or exceeded the effects of young blood on muscle repair, liver adiposity and fibrosis, and hippocampal neurogenesis. If dilution alone can...
Aging (Albany NY), 2020 · no headcount in the line
- no headcount stated0 studies
Mouse. A single exchange of half the plasma volume for saline with 5 percent albumin, adding nothing from a young animal, met or exceeded the effects of heterochronic blood sharing on muscle repair, liver adiposity and fibrosis, and hippocampal neurogenesis in old mice. Comparative proteomics on mouse and human...
Aging (Albany NY), 2020 · no headcount in the line
- no headcount stated0 studies
Diet-induced obese mice. Treated animals showed lower body weight, fat mass and plasma lipids, improved insulin sensitivity in white adipose tissue, and changes in the content and composition of glycerolipids, glycerophospholipids and sphingolipids alongside altered expression of lipid metabolism genes. A mouse...
iScience, 2021 · no headcount in the line
- no headcount stated0 studies
Synthesis and first characterisation. NMNH raised NAD to a much higher extent and faster than NMN or NR in mammalian cells, through an NRK-independent and NAMPT-independent pathway. It reduced damage and accelerated repair in renal tubular epithelial cells after hypoxia and reoxygenation injury. In mice,...
FASEB Journal, 2021 · no headcount in the line
- no headcount stated0 studies
- no headcount stated0 studies
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.